Corporate ActionApr 30, 2026, 04:48 PM
TOVX Special Meeting to Approve 16.18M Warrant Shares Issuance
AI Summary
Theriva Biologics, Inc. will hold a Special Meeting on June 5, 2026, to seek stockholder approval for the issuance of up to 16,184,560 shares of common stock upon the exercise of warrants issued in an October 2025 private placement. This approval is required by NYSE American rules and is crucial for the company to receive up to $8.7 million in gross proceeds from warrant exercises. The meeting will also address an adjournment proposal if insufficient votes are received, following three previous attempts that failed due to lack of quorum.
Key Highlights
- Special Meeting on June 5, 2026, to approve warrant exercise proposal.
- Approval sought for issuance of up to 16,184,560 common shares from warrants.
- Warrants issued in October 17, 2025 private placement at $0.54 exercise price.
- Potential gross proceeds of up to approximately $8.7 million if all warrants exercised for cash.
- Stockholder approval required by NYSE American Company Guide Section 713(a).
- Previous special meetings on Dec 15, 2025, Feb 11, 2026, and April 9, 2026, lacked quorum.
- Approval of the proposal will result in dilution for existing stockholders.
Price Impact
More from TOVX